EPHB2 is found to play a critical role in the progression from early-stage cutaneous squamous cell carcinoma to an advanced stage, and it is speculated to be a therapeutic target for invasive cutaneous squamous cell carcinoma [23]. Here, EPHB2 is linked to cutaneous squamous cell carcinoma.